

10/523,172

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN

10/523,172

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:03:27 ON 04 DEC 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:03:48 ON 04 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 DEC 2007 HIGHEST RN 956575-10-3

DICTIONARY FILE UPDATES: 3 DEC 2007 HIGHEST RN 956575-10-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

10/523,172

Uploading C:\Program Files\Stnexp\Queries\10523172.str



chain nodes :
1 2 3 4 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 24
25 26 28 29 31
ring nodes :
5 6 23
chain bonds :
1-2 2-3 2-12 3-4 4-5 4-13 6-7 6-14 7-8 7-24 8-9 8-15 9-10 9-25
10-11 10-17 11-18 11-26 15-16 16-31 18-19 19-20 19-21 21-22
24-29 26-28
ring bonds :
5-6 5-23 6-23
exact/norm bonds :
7-24 9-25 10-17 11-26 16-31 19-20 24-29 26-28
exact bonds :
1-2 2-3 2-12 3-4 4-5 4-13 5-6 5-23 6-7 6-14 6-23 7-8 8-9 8-15
9-10 10-11 11-18 15-16 18-19 19-21 21-22
isolated ring systems :
containing 5 :

G1:C,H,S,Si,Cy,Ak

10/523,172

G2:H,O,S,N,CN,Cy,Ak

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:CLASS 8:CLASS
9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS
16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS
23:Atom 24:CLASS 25:CLASS 26:CLASS 28:CLASS 29:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 17:04:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4 TO 200
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 17:04:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 61 TO ITERATE

100.0% PROCESSED 61 ITERATIONS 21 ANSWERS
SEARCH TIME: 00.00.01

L3 21 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 17:04:30 ON 04 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

10/523,172

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Dec 2007 VOL 147 ISS 24
FILE LAST UPDATED: 3 Dec 2007 (20071203/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 11 L3

=> d 14 ibib abs hitstr hitind

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:135655 CAPLUS

DOCUMENT NUMBER: 146:354941

TITLE: Myriaporones 1-4, Cytotoxic Metabolites from the Mediterranean Bryozoan Myriapora truncata

AUTHOR(S): Cheng, Jie-Fei; Lee, Jong-Soo; Sakai, Ryuichi; Jares-Erijman, Elizabeth A.; Silva, Maria V.; Rinehart, Kenneth L.

CORPORATE SOURCE: Roger Adams Laboratory, University of Illinois, Urbana, IL, 61801, USA

SOURCE: Journal of Natural Products (2007), 70(3), 332-336
CODEN: JNPRDF; ISSN: 0163-3864

PUBLISHER: American Chemical Society-American Society of Pharmacognosy

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Four novel polyketide-derived metabolites, myriaporones 1, 2, 3, and 4, have been isolated from the Mediterranean bryozoan Myriapora truncata. Their structures and stereochem. have been assigned from the anal. of spectroscopic data. The inseparable equilibrium mixture of

myriaporones 3 and 4 showed 88% inhibition of L1210 murine leukemia cells at 0.2 µg/mL.

IT 177481-41-3P, Myriaporone 4

RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)

(myriaporones 1-4 are cytotoxic metabolites from the Mediterranean bryozoan Myriapora truncata)

RN 177481-41-3 CAPLUS

CN 3,7-Nonanedione,

1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-


3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA

INDEX

10/523,172

NAME)

Absolute stereochemistry.
Double bond geometry as shown.



CC 12-1 (Nonmammalian Biochemistry)

Section cross-reference(s): 1

IT 177481-40-2P, Myriaporone 3 177481-41-3P, Myriaporone 4

RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)

(myriaporones 1-4 are cytotoxic metabolites from the Mediterranean bryozoan *Myriapora truncata*)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD: ALL CITATIONS AVAILABLE IN THE RE

=> d 14 ibib abs hitstr hitind 2-11

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:855160 CAPLUS

DOCUMENT NUMBER: 146:265756

TITLE: Myriaporone 3/4 structure-activity relationship studies define a pharmacophore targeting eukaryotic protein synthesis

AUTHOR(S): Hines, John; Roy, Myriam; Cheng, Hua; Agapakis, Christina M.; Taylor, Richard; Crews, Craig M.

CORPORATE SOURCE: Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, 06520-8103,

SOURCE: USA
Molecular BioSystems (2006), 2(8), 371-379
CODEN: MBOIBW; ISSN: 1742-206X

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Myriaporones are naturally occurring compds. which structurally resemble


the southern hemisphere of the tedanolide family of macrolide antitumor agents. Despite the fact that myriaporone 3/4 represents only a portion

of tedanolide, it nonetheless retains much of its biol. activity. We show here that like tedanolide, myriaporone 3/4 inhibits protein synthesis and proliferation of mammalian cells with low nanomolar potencies but displays no prokaryotic growth inhibitory effect. Moreover, myriaporone 3/4 displays a very rapid, reversible and p21-independent activity to block S phase progression in mammalian cells. Structure-activity relation studies revealed that the C18-C19 epoxide and the C14 hydroxymethyl group (tedanolide numbering) of myriaporone 3/4 are required for cell cycle inhibition. These constitute previously unidentified and/or novel pharmacophores for myriaporone 3/4. Our results show that the important biol. activities associated with the structurally complex tedanolides are present and can be harnessed in the chemical much simpler myriaporones. This greatly increases the value of the latter as investigative tools for biochem. research as well as for development of potential therapeutics.

IT 926927-79-9 926927-80-2
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (myriaporone 3/4 structure-activity relationship studies define pharmacophore targeting eukaryotic protein synthesis)


RN 926927-79-9 CAPLUS
 CN D-glycero-L-gulo-Heptitol,
 3,4-anhydro-1,2,6-trideoxy-6-[(2R,3S)-3-hydroxy-2-methyl-1,5-dioxoheptyl]-4-C-methyl-2-(1Z)-1-propen-1-yl- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 926927-80-2 CAPLUS
 CN D-glycero-L-gulo-Heptitol,
 3,4-anhydro-1,2,6-trideoxy-6-[(2R,3R)-3-hydroxy-2-methyl-1,5-dioxoheptyl]-4-C-methyl-2-(1Z)-1-propen-1-yl- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 177481-41-3, Myriaporone 4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (myriaporone 3/4 structure-activity relationship studies define
 pharmacophore targeting eukaryotic protein synthesis)
 RN 177481-41-3 CAPLUS
 CN 3,7-Nonanedione,
 1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-
 3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA
 INDEX
 NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




CC 1-3 (Pharmacology)
 IT 926927-77-7 926927-78-8 926927-79-9 926927-80-2
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (myriaporone 3/4 structure-activity relationship studies define
 pharmacophore targeting eukaryotic protein synthesis)
 IT 177481-40-2, Myriaporone 3 177481-41-3, Myriaporone 4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (myriaporone 3/4 structure-activity relationship studies define
 pharmacophore targeting eukaryotic protein synthesis)
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:689835 CAPLUS
 DOCUMENT NUMBER: 144:128783

10/523,172

TITLE: Total synthesis of the cytotoxic natural products myriaporones 1, 3, and 4 and related analogues
AUTHOR(S): Fleming, Kristen Nicole
CORPORATE SOURCE: Univ. of Notre Dame, Notre Dame, IN, USA
SOURCE: (2004) 320 pp. Avail.: UMI, Order No. DA3147383
From: Diss. Abstr. Int., B 2005, 65(9), 4576
DOCUMENT TYPE: Dissertation
LANGUAGE: English
AB Unavailable
IT 177481-41-3P, Myriaporone 4
RL: SPN (Synthetic preparation); PREP (Preparation)
(Total synthesis of the cytotoxic natural products myriaporones 1, 3, and 4 and related analogs)
RN 177481-41-3 CAPLUS
CN 3,7-Nonanedione,
1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA
INDEX
NAME)

Absolute stereochemistry.
Double bond geometry as shown.



CC 26-9 (Biomolecules and Their Synthetic Analogs)
IT 177481-40-2P, Myriaporone 3 177481-41-3P, Myriaporone 4
447461-47-4P, Myriaporone 1
RL: SPN (Synthetic preparation); PREP (Preparation)
(Total synthesis of the cytotoxic natural products myriaporones 1, 3, and 4 and related analogs)
L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:290702 CAPLUS
DOCUMENT NUMBER: 141:6963
TITLE: Total synthesis and stereochemical assignment of myriaporones 1, 3, and 4
AUTHOR(S): Fleming, Kristen N.; Taylor, Richard E.
CORPORATE SOURCE: Department of Chemistry and Biochemistry,
University of Notre Dame, Notre Dame, IN, 46556-5670, USA
SOURCE: Angewandte Chemie, International Edition (2004), 43(13), 1728-1730

CODEN: ACIEF5; ISSN: 1433-7851

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:6963

AB Two stereoselective aldol reactions, a nitrile oxide cycloaddn., and a stereoselective late-stage epoxidn. were key steps in the total synthesis

of myriaporones 1, 3, and 4. The synthesis allowed the unambiguous assignment of stereogenic centers not previously assigned for these compds.

IT 692749-40-9P 692749-55-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)

(total synthesis and stereochem. assignment of myriaporones 1, 3, and 4)


RN 692749-40-9 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradecoxy-1-O-

[(1,1-dimethylethyl)dimethylsilyl]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-[(1S)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.




RN 692749-55-6 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradecoxy-1-O-

[(1,1-dimethylethyl)dimethylsilyl]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-[(1R)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



IT 177481-41-3P, Myriaporone 4 651356-66-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(total synthesis and stereochem. assignment of myriaporones 1, 3,

and

4)

RN 177481-41-3 CAPLUS

CN 3,7-Nonanedione,

1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-


3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA

INDEX

NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 651356-66-0 CAPLUS


CN D-glycero-D-gulo-D-glycero-3-Nonulose,

6,7-anhydro-2,4,8,9-tetradecoxy-4-

(hydroxymethyl)-2-[(1R)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



CC 26-9 (Biomolecules and Their Synthetic Analogs)

IT 648883-76-5P 692749-33-0P 692749-34-1P 692749-35-2P

692749-36-3P

692749-37-4P 692749-38-5P 692749-39-6P 692749-40-9P

692749-41-0P 692749-42-1P 692749-43-2P 692749-44-3P

692749-45-4P

692749-46-5P 692749-47-6P 692749-48-7P 692749-49-8P

692749-50-1P

692749-51-2P 692749-52-3P 692749-53-4P 692749-54-5P

692749-55-6P 692749-56-7P 692749-57-8P 727985-23-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)

(total synthesis and stereochem. assignment of myriaporones 1, 3,

and

4)

IT 177481-40-2P, Myriaporone 3 177481-41-3P, Myriaporone 4

447461-47-4P, Myriaporone 1 651356-66-0P 693782-35-3P,

5-epi-Myriaporone 1

RL: SPN (Synthetic preparation); PREP (Preparation)

(total synthesis and stereochem. assignment of myriaporones 1, 3,

and

4)

REFERENCE COUNT:
THIS

26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:290701 CAPLUS

DOCUMENT NUMBER: 141:6962

TITLE: Total synthesis of natural myriaporones

AUTHOR(S): Perez, Marta; del Pozo, Carlos; Ryeas, Fernando;
Rodriguez, Alberto; Francesch, Andres; Echavarren,
Antonio M.; Cuevas, Carmen

CORPORATE SOURCE: Departamento de Quimica Organica, Universidad
Autonoma

SOURCE: de Madrid, Madrid, 28049, Spain
Angewandte Chemie, International Edition (2004),
43(13), 1724-1727

PUBLISHER: CODEN: ACIEF5; ISSN: 1433-7851
Wiley-VCH Verlag GmbH & Co. KGaA

10/523,172

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:6962

AB The relative and absolute configuration of the cytotoxic myriaporones (e.g. 4)

was assigned by their total synthesis from aldehyde 1. Key steps included

aldol reactions with chiral oxazolidinone 2 and with Weinreb amide 3.

TBS

= tert-butyldimethylsilyl, PMB =p-methoxybenzyl.

IT 177481-41-3P, Myriaporone 4

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(absolute configuration and total synthesis of natural myriaporones from an aldehyde via a stereoselective aldol reaction)

RN 177481-41-3 CAPLUS

CN 3,7-Nonanedione,


1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA

INDEX

NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 651355-81-6P 651356-00-2P 651356-64-8P

651356-74-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)

(absolute configuration and total synthesis of natural myriaporones from an

aldehyde via a stereoselective aldol reaction)

RN 651355-81-6 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,


6,7-anhydro-2,4,8,9-tetradexoy-1,5-

bis-O-[(1,1-dimethylethyl)dimethylsilyl]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-[(1S)-1-[[[(1,1-

dimethylethyl)dimethylsilyl]oxy]-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-(9CI) (CA INDEX NAME)

10/523,172

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.




RN 651356-00-2 CAPLUS

CN D-glycero-D-gulo-L-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradecoxy-1,5-

bis-O-[(1,1-dimethylethyl)dimethylsilyl]-4-[[[(1,1-
dimethylethyl)dimethylsilyl]oxy]methyl]-2-[(1S)-1-[(1,1-

dimethylethyl)dimethylsilyl]oxy]-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.




RN 651356-64-8 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradecoxy-1,5-

10/523,172

bis-O-[(1,1-dimethylethyl)dimethylsilyl]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-[(1R)-1-[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 651356-74-0 CAPLUS


CN D-glycero-D-gulo-L-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradeoxy-1,5-

bis-O-[(1,1-dimethylethyl)dimethylsilyl]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-[(1R)-1-[(1,1-

dimethylethyl)dimethylsilyl]oxy]-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

10/523,172



IT 651355-82-7P 651356-66-0P 651356-76-2P

695196-79-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(absolute configuration and total synthesis of natural myriaporones
from an aldehyde via a stereoselective aldol reaction)


RN 651355-82-7 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradecoxy-5-O-

[(1,1-dimethylethyl)dimethylsilyl]-4-(hydroxymethyl)-2-[(1S)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 651356-66-0 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradecoxy-4-

(hydroxymethyl)-2-[(1R)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl- (9CI) (CA INDEX NAME)


10/523,172

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 651356-76-2 CAPLUS
CN D-glycero-D-gulo-L-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradecoxy-4-
(hydroxymethyl)-2-[(1R)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-
propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 695196-79-3 CAPLUS
CN D-glycero-D-gulo-L-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradecoxy-4-
(hydroxymethyl)-2-[(1S)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-
propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



CC 26-9 (Biomolecules and Their Synthetic Analogs)
IT 177481-41-3P, Myriaporone 4
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP

10/523,172

(Preparation); RACT (Reactant or reagent)
(absolute configuration and total synthesis of natural myriaporones
from an aldehyde via a stereoselective aldol reaction)

IT 651355-67-8P 651355-69-0P 651355-70-3P 651355-71-4P
651355-72-5P
651355-73-6P 651355-74-7P 651355-76-9P 651355-79-2P
651355-80-5P
651355-81-6P 651355-83-8P 651355-84-9P 651355-86-1P
651355-88-3P 651355-96-3P 651355-98-5P 651356-00-2P
651356-55-7P 651356-58-0P 651356-60-4P 651356-62-6P
651356-64-8P 651356-68-2P 651356-72-8P 651356-73-9P
651356-74-0P 695196-80-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)

(absolute configuration and total synthesis of natural myriaporones
from an aldehyde via a stereoselective aldol reaction)

IT 651355-82-7P 651356-66-0P 651356-76-2P
695196-79-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(absolute configuration and total synthesis of natural myriaporones
from an aldehyde via a stereoselective aldol reaction)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:101159 CAPLUS

DOCUMENT NUMBER: 140:145931

TITLE: Total synthesis of myriaporones as antitumor agents

INVENTOR(S): Perez Alvarez, Marta; Del Pozo Losada, Carlos;

Francesch Solloso, Andres; Cuevas Marchante, Carmen

PATENT ASSIGNEE(S): Pharma Mar, S.A.U., Spain; Ruffles, Graham Keith

SOURCE: PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011458	A1	20040205	WO 2003-GB3327	20030730
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,			

10/523,172

	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW				
RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,	
	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GO,	GW,	ML,	MR,	NE,	SN,	TD,	TG	

CA 2494532	A1	20040205	CA 2003-2494532	20030730
AU 2003248984	A1	20040216	AU 2003-248984	20030730
EP 1532139	A1	20050525	EP 2003-771210	20030730
EP 1532139	B1	20070613		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1684956	A	20051019	CN 2003-823314	20030730
JP 2006504659	T	20060209	JP 2004-523987	20030730
NZ 537678	A	20061130	NZ 2003-537678	20030730
AT 364603	T	20070715	AT 2003-771210	20030730
MX 2005PA01176	A	20050912	MX 2005-PA1176	20050128
US 2006084819	A1	20060420	US 2005-523172	20050128
NO 2005001037	A	20050413	NO 2005-1037	20050225
IN 2007DN07476	A	20071102	IN 2007-DN7476	20070927

PRIORITY APPLN. INFO.:

GB 2002-17638 / A 20020730

WO 2003-GB3327 W 20030730


IN 2005-DN335 A3 20050128

US 2005-523172 A 20050128


OTHER SOURCE (S) :

MARPAT 140:145931

GI-



I



II

AB Myriaporones of formula I [R = H, trialkylsilyl, acyl, etc.; R1 = H, (substituted) OH, acyloxy, SH, CHO, CO2H, CH2OH, NH2, etc.] are prepared as

10/523,172

antitumor agents. Thus, II was prepared in several steps. and shown to have

activity against a number of tumor cell lines.

IT 177481-41-3P 651355-81-6P 651356-00-2P
651356-02-4P 651356-64-8P 651356-74-0P
651356-75-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis of myriaporones as antitumor agents)

RN 177481-41-3 CAPLUS


CN 3,7-Nonanedione,

1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA

INDEX
NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 651355-81-6 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,

6,7-anhydro-2,4,8,9-tetradecoxy-1,5-


bis-O-[(1,1-dimethylethyl)dimethylsilyl]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-[(1S)-1-[(1,1-

dimethylethyl)dimethylsilyl]oxy]-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Double bond geometry as shown.

10/523,172



RN 651356-00-2 CAPLUS

CN D-glycero-D-gulo-L-glycero-3-Nonulose,


6,7-anhydro-2,4,8,9-tetradecoxy-1,5-

bis-O-[(1,1-dimethylethyl)dimethylsilyl]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2-[(1S)-1-[[[(1,1-

dimethylethyl)dimethylsilyl]oxy]-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-(9CI). (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Double bond geometry as shown.



RN 651356-02-4 CAPLUS

CN D-glycero-D-gulo-L-glycero-3-Nonulose,

6,7-anhydro-2,4,8,9-tetradecoxy-5-O-


[(1,1-dimethylethyl)dimethylsilyl]-4-(hydroxymethyl)-2-[(1S)-1-hydroxy-3-[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-(9CI). (CA INDEX NAME)

10/523,172

oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 651356-64-8 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,

6,7-anhydro-2,4,8,9-tetradecoxy-1,5-


bis-O-[(1,1-dimethylethyl)dimethylsilyl]-4-[[[(1,1-

dimethylethyl)dimethylsilyl]oxy)methyl]-2-[(1R)-1-[[[(1,1-

dimethylethyl)dimethylsilyl]oxy]-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



RN 651356-74-0 CAPLUS

CN D-glycero-D-gulo-L-glycero-3-Nonulose,

6,7-anhydro-2,4,8,9-tetradecoxy-1,5-


bis-O-[(1,1-dimethylethyl)dimethylsilyl]-4-[[[(1,1-

dimethylethyl)dimethylsilyl]oxy)methyl]-2-[(1R)-1-[[[(1,1-

10/523,172

dimethylethyl)dimethylsilyl]oxy]-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



RN 651356-75-1 CAPLUS
CN D-glycero-D-gulo-L-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradecoxy-5-O-

[(1,1-dimethylethyl)dimethylsilyl]-4-(hydroxymethyl)-2-[(1R)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 177481-41-3P 651355-82-7P 651356-18-2P
651356-20-6P 651356-22-8P 651356-23-9P
651356-25-1P 651356-65-9P 651356-66-0P
651356-76-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

10/523,172

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of myriaporones as antitumor agents)

RN 177481-41-3 CAPLUS

CN 3,7-Nonanedione,


1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA

INDEX

NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 651355-82-7 CAPLUS


CN D-glycero-D-gulo-D-glycero-3-Nonulose,

6,7-anhydro-2,4,8,9-tetradecoxy-5-O-

[(1,1-dimethylethyl)dimethylsilyl]-4-(hydroxymethyl)-2-[(1S)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 651356-18-2 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,


4-[(acetyloxy)methyl]-6,7-anhydro-

2,4,8,9-tetradecoxy-5-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1R)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl- (9CI) (CA INDEX

NAME)


10/523,172

Absolute stereochemistry.
Double bond geometry as shown.



RN 651356-20-6 CAPLUS
CN D-glycero-D-gulo-D-glycero-3-Nonulose,
4-[(acetyloxy)methyl]-6,7-anhydro-
2,4,8,9-tetradecoxy-5-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1R)-1-
hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl-, 1-acetate (9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 651356-22-8 CAPLUS
CN D-glycero-D-gulo-D-glycero-3-Nonulose, 4-[(acetyloxy)methyl]-2-[(1R)-1-
(acetyloxy)-3-oxopentyl]-6,7-anhydro-2,4,8,9-tetradecoxy-5-O-[(1,1-
dimethylethyl)dimethylsilyl]-6-C-methyl-8-(1Z)-1-propenyl-, 1-acetate
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

10/523,172



RN 651356-23-9 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,

4-[(acetyloxy)methyl]-6,7-anhydro-


2,4,8,9-tetradecoxy-5-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1S)-1-

hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 651356-25-1 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,

4-[(acetyloxy)methyl]-6,7-anhydro-


2,4,8,9-tetradecoxy-2-[(1S)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-

propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

10/523,172




RN 651356-65-9 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradeoxy-5-O-

[(1,1-dimethylethyl)dimethylsilyl]-4-(hydroxymethyl)-2-[(1R)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 651356-66-0 CAPLUS

CN D-glycero-D-gulo-D-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradeoxy-4-

(hydroxymethyl)-2-[(1R)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.




RN 651356-76-2 CAPLUS

10/523,172

CN D-glycero-D-gulo-L-glycero-3-Nonulose,
6,7-anhydro-2,4,8,9-tetradecoxy-4-
(hydroxymethyl)-2-[(1R)-1-hydroxy-3-oxopentyl]-6-C-methyl-8-(1Z)-1-
propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IC ICM C07D407-06
ICS C07D493-08; C07D303-32; A61P035-00; A61K031-35; C07D309-00;
C07D317-00; C07D307-00
CC 26-9 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 63
IT 177481-41-3P 651355-62-3P 651355-63-4P 651355-81-6P
651356-00-2P 651356-02-4P 651356-64-8P
651356-74-0P 651356-75-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis of myriaporones as antitumor agents)
IT 177481-41-3P 447461-47-4P 651355-82-7P
651356-18-2P 651356-20-6P 651356-22-8P
651356-23-9P 651356-25-1P 651356-65-9P
651356-66-0P 651356-76-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(synthesis of myriaporones as antitumor agents)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:883033 CAPLUS
DOCUMENT NUMBER: 136:340516
TITLE: A zirconium-mediated allylation approach to the
total
synthesis of tedanolide and the myriaporones
AUTHOR(S): Hearn, Brian R.
CORPORATE SOURCE: Univ. of Notre Dame, Notre Dame, IN, USA
SOURCE: (2001) 220 pp. Avail.: UMI, Order No. DA9999811
From: Diss. Abstr. Int., B 2001, 61(12), 6478

10/523,172

DOCUMENT TYPE: Dissertation

LANGUAGE: English

* AB Unavailable

IT 177481-41-3P, Myriaporone 4

RL: PNU (Preparation, unclassified); PREP (Preparation)
(zirconium-mediated allylation approach to the total synthesis of
tedanolide and the myriaporones)

RN 177481-41-3 CAPLUS


CN 3,7-Nonanedione,

1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-
3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA

INDEX
NAME)

Absolute stereochemistry.

Double bond geometry as shown.



CC 26-9 (Biomolecules and Their Synthetic Analogs)

IT 92471-87-9P 177481-41-3P, Myriaporone 4

RL: PNU (Preparation, unclassified); PREP (Preparation)
(zirconium-mediated allylation approach to the total synthesis of
tedanolide and the myriaporones)

L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:788201 CAPLUS

DOCUMENT NUMBER: 134:86078

TITLE: Studies on the synthesis of myriaporones:
stereoselective synthesis of the C5-C13 fragment
starting from D-glucose via regioselective

reductive

AUTHOR(S): opening of methoxybenzylidene acetal
Zheng, Bao-Zhong; Yamauchi, Megumi; Dei, Hiroo;
Yonemitsu, Osamu

CORPORATE SOURCE: Department of Chemistry, Okayama University of
Science, Okayama, 700-0005, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (2000), 48(11),
1761-1765

CODEN: CPBTAL; ISSN: 0009-2363


PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:86078

GI



AB A stereoselective synthesis is described of the C5-C13 fragment (I) of myriaporone 4 starting from D-glucose by a coupling of the C5-C9 aldehyde, prepared using a regioselective reductive ring-opening of methoxybenzylidene acetal, with the C10-C13 iodoolefin.

IT 177481-41-3P, Myriaporone 4

RL: PNU (Preparation, unclassified); PREP (Preparation) (stereoselective synthesis of the C5-C13 fragment of myriaporone 4 starting from D-glucose via regioselective reductive opening of methoxybenzylidene acetal)

RN 177481-41-3 CAPLUS

CN 3,7-Nonanedione,


1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA

INDEX

NAME)

Absolute stereochemistry.

Double bond geometry as shown.



CC 26-9 (Biomolecules and Their Synthetic Analogs)

Section cross-reference(s): 33

IT 177481-41-3P, Myriaporone 4

RL: PNU (Preparation, unclassified); PREP (Preparation) (stereoselective synthesis of the C5-C13 fragment of myriaporone 4 starting from D-glucose via regioselective reductive opening of methoxybenzylidene acetal)

10/523,172

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:561469 CAPLUS

DOCUMENT NUMBER: 133:321748

TITLE: Facile chelation-controlled reductive opening of methoxybenzylidene acetals with Bu₃SnH and MgBr₂. Regioselective protection strategy as MPM ethers
AUTHOR(S): Zheng, Bao-Zhong; Yamauchi, Megumi; Dei, Hiroo; Kusaka, Shin-ichi; Matsui, Katsuya; Yonemitsu,

Osamu

CORPORATE SOURCE: Department of Chemistry, Okayama University of Science, Okayama, 700-0005, Japan

SOURCE: Tetrahedron Letters (2000), 41(33), 6441-6445
CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 133:321748

AB A mild and efficient regioselective reductive opening of methoxybenzylidene acetals using a combination of Bu₃SnH and MgBr₂·OEt₂, mainly via five-membered chelation intermediates, is described. This reaction was applied to synthetic intermediates of natural products such as tedanolide and myriaporone.

IT 177481-41-3P, Myriaporone 4

RL: PNU (Preparation, unclassified); PREP (Preparation)
((methoxy)benzylidene ethers as regioselective protective groups for the synthesis of intermediates for natural products)

RN 177481-41-3 CAPLUS

CN 3,7-Nonanedione,


1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA

INDEX

NAME)

Absolute stereochemistry.

Double bond geometry as shown.



CC 26-9 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 33

10/523,172

IT 92471-87-9P, Tedanolide 177481-40-2P, Myriaporone 3 177481-41-3P
, Myriaporone 4
RL: PNU (Preparation, unclassified); PREP (Preparation)
((methoxy)benzylidene ethers as regioselective protective groups for
the synthesis of intermediates for natural products)
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:809492 CAPLUS

DOCUMENT NUMBER: 130:153496

TITLE: A divergent approach to the myriaporones and
tedanolide: enantioselective preparation of the
common

intermediate
AUTHOR(S): Taylor, Richard E.; Ciavarri, Jeffrey P.; Hearn,
Brian

R.
CORPORATE SOURCE: Department of Chemistry and Biochemistry,
University

of Notre Dame, Notre Dame, IN, 46556, USA
SOURCE: Tetrahedron Letters (1998), 39(51), 9361-9364
CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 130:153496

AB The tedanolide and myriaporone classes of natural products represent
interesting targets for synthesis because of their structural
similarity

and biol. activity. The asym. preparation of a potential common
intermediate

in the total synthesis of each of these targets was accomplished. The
key

step, a Zr-mediated allylation, allowed for the efficient preparation
of the

hydroxypropionate structural unit.

IT 177481-41-3P, Myriaporone 4

RL: PNU (Preparation, unclassified); PREP (Preparation)
(enantioselective preparation of the common intermediate for the
natural

products tedanolide and myriaporone)

RN 177481-41-3 CAPLUS

CN 3,7-Nonanedione,

1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-
3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA


INDEX

NAME)

Absolute stereochemistry.

10/523,172

Double bond geometry as shown.



CC 26-9 (Biomolecules and Their Synthetic Analogs)
IT 92471-87-9P, Tedanolide 177481-40-2P, Myriaporone 3 177481-41-3P
, Myriaporone 4
RL: PNU (Preparation, unclassified); PREP (Preparation)
(enantioselective preparation of the common intermediate for the
natural
products tedanolide and myriaporone)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE



FORMAT

L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:333055 CAPLUS
DOCUMENT NUMBER: 125:5896
TITLE: Cytotoxic metabolites from Myriapora truncata
INVENTOR(S): Rinehart, Kenneth L.; Cheng, Jie-Fei; Lee, Jong-Soo
PATENT ASSIGNEE(S): Pharmamar, S.A., Spain
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5514708	A	19960507	US 1994-198444	19940218
PRIORITY APPLN. INFO.:			US 1994-198444	19940218

GL

10/523,172



AB The present invention is based upon the discovery that the methanol extract of the bryozoan *Myriapora truncata* showed potent cytotoxicity against L1210 murine leukemia cells (99% inhibition at 50 µg/mL). Fractionation and purification of active components from this extract, guided by a cytotoxicity assay, resulted in the isolation of a novel, highly cytotoxic polyketide-derived metabolite MT-332 (I) and its equilibrium isomer (II), along with two less active compds., MT-381 and MT-381-B. The equilibrium mixture of Compds. I and II showed 88% inhibition at 0.2 µg/mL against L1210 cells.

IT 177481-41-3

RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties);

BIOL

(Biological study); OCCU (Occurrence) (natural product isolation and structural characterization and cytotoxic activity from bryozoan)

RN 177481-41-3 CAPLUS

CN 3,7-Nonanedione,

1,5-dihydroxy-2,4-bis(hydroxymethyl)-1-[(2R,3R)-2-methyl-3-[(1S,2Z)-1-methyl-2-buten-1-yl]-2-oxiranyl]-, (1S,2R,4R,5S)- (CA


INDEX

NAME)

Absolute stereochemistry.

10/523,172

Double bond geometry as shown.



IC ICM A61K031-35
ICS A61K031-335; C07D309-10; C07D303-32
INCL 514460000
CC 12-1 (Nonmammalian Biochemistry)
Section cross-reference(s): 26
IT 177481-40-2 177481-41-3
RL: BAC (Biological activity or effector, except adverse); BOC
(Biological
occurrence); BSU (Biological study, unclassified); PRP (Properties);
BIOL (Biological study); OCCU (Occurrence)
(natural product isolation and structural characterization and
cytotoxic activity from bryozoan)

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
59.82	232.13

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-7.02	-7.02

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 17:06:03 ON 04 DEC 2007